- Extending GenVoy-ILM product line to accelerate mRNA and saRNA vaccine development
- GMP-compatible lipids ensure scalability for large-scale manufacturing
September 9, 2024
Cytiva introduces its latest innovation, the RNA delivery LNP kit, specifically designed for use with the NanoAssemblr Ignite and Ignite+ systems. This new product complements the GenVoy-ILM off-the-shelf LNP kits product line, set to transform RNA-LNP delivery, particularly in infectious disease vaccine development.
Scott Ripley, VP & GM for Nucleic Acid Therapeutics & Nanomedicine at Cytiva, says: "Our new RNA delivery LNP kit is designed to make the development of RNA-based therapeutics more accessible and efficient. By offering a comprehensive, ready-to-use solution, we're helping researchers move more quickly from discovery to clinical trials. This kit ensures the production of high-quality, stable lipid nanoparticles, which is crucial for the success of RNA-based treatments."
NanoAssemblr Ignite and RNA delivery LNP kits
The RNA delivery LNP kit offers a ready-to-use ionizable lipid mix for rapid payload screening and RNA drug delivery validation. By advancing lead candidates through preclinical studies quickly, it accelerates clinical evaluation. This kit lowers the barrier for vaccine developers by providing protocols and proof-of-concept data for mRNA and saRNA delivery in infectious disease models. It includes a lipid excipient available for licensing through to commercialization.
Key Features:
- Pre-optimized Ionizable Lipid Mix: Tailored for RNA-LNP delivery to accelerate lead candidate selection.
- Rapid and Easy Preparation: Facilitates high-quality, stable LNP production using prepared reagents and protocols.
- Scalability: Seamless integration with the NanoAssemblr system platform and availability of GMP lipid components.
- Validation: Proven efficacy in delivering mRNA and saRNA for infectious disease vaccine applications, with scalability for clinical evaluation through licensing.
Tailored for developers in discovery and early preclinical stages, the kit accelerates nanomedicine development with formulations that transition smoothly from clinical evaluation to commercial success. It benefits customers needing lipid mixes and formulations for discovery and target validation, especially those with limited in-house expertise. Leveraging this LNP technology helps achieve key milestones, validate technology, and secure funding or collaborators. The inclusion of GMP-compatible lipids ensures scalability for large-scale manufacturing.
Learn more about our lipid nanoparticle reagents here.
NanoAssemblr, Ignite, Ignite+, GenVoy-ILM and Cytiva are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers.
Learn more at cytivalifesciences.com
Media Contact:
Doug Kim
[email protected]